Nombre del producto:2-Amino-4-fluoropyridine

IUPAC Name:4-fluoropyridin-2-amine

CAS:944401-77-8
Fórmula molecular:C5H5FN2
Pureza:95%+
Número de catálogo:CM120536
Peso molecular:112.11

Unidad de embalaje Stock disponible Precio($) Cantidad
CM120536-10g in stock DzƋ
CM120536-25g in stock ȦDzȌ
CM120536-100g in stock ɐǕǕ
CM120536-500g in stock ȷȦǕǕ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :944401-77-8
Fórmula molecular:C5H5FN2
Punto de fusión:-
Código de sonrisas:FC1=CC(N)=NC=C1
Densidad:
Número de catálogo:CM120536
Peso molecular:112.11
Punto de ebullición:211.5°C at 760 mmHg
Nº Mdl:MFCD09260906
Almacenamiento:Keep in dark place, store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

IDRX-42
IDRx announces $120 million series B financing to advance potential best-in-class new treatment for gastrointestinal stromal tumor (GIST). IDRX-42 is a potent, oral, highly selective KIT inhibitor targeting all major categories of activating and resistance mutations in patients with KIT-mutant GIST (including variants in exons 9, 11, 13 and 17). IDRX-42 was granted Orphan Drug designation by the FDA for the treatment of GIST. IDRX-42 is currently being evaluated in StrateGIST 1, a first-in-human Phase 1/1b study.
In preclinical studies, IDRX-42 demonstrated superior antitumor activity compared to imatinib, the current first-line of therapy, in GIST human xenograft models expressing mutations in KIT exons 9 and 11. In xenograft models expressing secondary resistance mutations in KIT exon 13 or 17, IDRX-42 treatment resulted in potent and dose-dependent antitumor activity superior to the second-line standard of care agent, sunitinib.

Related Products